EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
Rhea-AI Summary
EDAP (Nasdaq: EDAP) signed a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinical research and physician education in prostate cancer. The collaboration centers on integrating Focal One Robotic HIFU with Telix’s PSMA PET imaging to enhance diagnosis, treatment planning, and follow-up.
The parties may develop clinical studies and training for mutual customers in primary and salvage treatment settings. There are no financial commitments, no binding obligations to proceed, and the collaboration is not expected to materially impact EDAP’s financial results.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus
EDAP was modestly higher by 1.96% while peers showed mixed moves: OMI up 2.19%, COSM down 4.45%, ZYXI down sharply by 37.34%, and YI slightly higher. Momentum scanners only flagged YI moving down, reinforcing a stock-specific read for this collaboration news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | +15.7% | Record HIFU revenue and strong Focal One system placements with rising procedures. |
| Apr 30 | Clinical study data | Positive | +0.3% | Prospective HIFI-2 salvage HIFU data showing favorable outcomes and safety profile. |
| Apr 16 | Earnings date notice | Neutral | +2.0% | Announcement of timing and access details for upcoming Q1 2026 results call. |
| Mar 25 | FY 2025 results | Positive | -5.1% | Record 2025 HIFU revenue and reiterated 2026 guidance for continued growth. |
| Mar 10 | Conference presentation | Neutral | +4.8% | Oppenheimer MedTech conference appearance and investor meetings schedule disclosure. |
Positive operational and clinical updates often see supportive or modestly positive reactions, but one strong growth update drew a negative move, indicating occasional divergence.
Over recent months, EDAP has highlighted growth in its HIFU franchise and expanding clinical evidence. On Mar 25, record 2025 HIFU revenue and reiterated 2026 guidance coincided with a -5.12% move, while strong Q1 2026 results on May 7 saw a +15.72% reaction. The HIFI-2 study summary on Apr 30 produced a small gain, and conference or scheduling announcements showed modest positives. Today’s Telix collaboration fits the pattern of building the Focal One ecosystem and clinical positioning in prostate cancer.
Regulatory & Risk Context
EDAP has an effective S-3/A shelf registration dated 2026-03-26, with at least one prospectus supplement filed (424B3 on 2026-03-31). The latest amendment was exhibit-only and did not alter the prospectus terms, indicating an established framework for potential future securities offerings.
Market Pulse Summary
This announcement outlines a non-binding letter of intent with Telix to integrate PSMA PET imaging into the Focal One Robotic HIFU workflow for prostate cancer, covering both primary and salvage settings. No financial commitments were made, and EDAP does not expect a material impact on financial results. In context of recent record HIFU revenue and supportive HIFI-2 data, this collaboration extends EDAP’s strategy of strengthening Focal One’s clinical role while leaving funding, execution, and adoption as key future watch points.
Key Terms
hifu medical
psma pet medical
theranostics medical
focal therapy medical
ultrasound medical
salvage treatment medical
AI-generated analysis. Not financial advice.
, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of EDAP’s Focal One Robotic HIFU and Telix’s PSMA PET imaging products in the management of prostate cancer.
The initial area of investigational focus is expected to study the combination of PSMA PET diagnostic imaging scans within the Focal One HIFU treatment workflow to optimize treatment planning, deliver a precise, image-guided focal therapy treatment, and monitor responses after treatment and during subsequent patient follow-up. This collaboration will be investigated in both the primary treatment setting as well as the salvage treatment setting after radiation therapy.
Based on early clinical experience integrating PSMA PET with Focal One HIFU and with the recently published prospective HIFI-2 study showing positive patient outcomes using Focal One to treat patients with recurrence after radiation therapy, this combination with Telix holds the promise to further improve patient outcomes.
“We are uniquely designed to enable the integration of PSMA PET imaging with Focal One’s real-time ultrasound and fully robotic energy delivery to optimize treatment efficacy while minimizing side effects,” said Ryan Rhodes, EDAP Chief Executive Officer. “As the market leader in robotic focal therapy, with a growing global installed base, this collaboration will accelerate the development and standardization of treatment strategies to further personalize focal therapy treatments using Telix’s PSMA PET imaging agents and Focal One Robotic HIFU.”
“Precision medicine requires precision treatment strategies,” said Kevin Richardson, Telix Precision Medicine Chief Executive Officer. “As disruptive technologies continue to transform prostate cancer care, we believe PSMA PET imaging has the potential to play an important role in helping clinicians better inform treatment decisions across a range of minimally invasive and image-guided treatment approaches. We are excited to explore a collaboration with Focal One that may further advance personalized care for patients.”
The parties may also explore clinician educational programs such as webinars, symposia, and training initiatives and clinical studies involving mutual customers managing patients with Telix PSMA PET imaging products and Focal One Robotic HIFU.
The parties may enter into more definitive agreements in the future. There can be no assurance that any specific initiatives or programs will result from this initial collaboration, and the letter of intent imposes no obligation on either party to enter into any such agreement. The parties have not made any financial commitments under the letter of intent, and the collaboration is not expected to have a material impact on EDAP's financial results.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics, and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and the United States as a leading prostate focal therapy platform controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit www.telixpharma.com for further information about Telix.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, risks specific to the announced collaboration with Telix Pharmaceuticals Limited, including the possibility that the parties do not enter into definitive agreements, that any contemplated clinical or educational activities are delayed, modified, or do not occur, that anticipated benefits of the collaboration are not realized, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.
Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 10-K.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Investor Contact
Louisa Smith
Gilmartin Group
investor.relations@focalone.com
